Organon (OGN) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
9 Jun, 2026Opening remarks and agenda
The meeting was opened virtually to increase inclusivity and participation, with shareholders able to vote and ask questions online.
The agenda included introductions, formal business, and voting on key proposals.
Rules of conduct and technical support information were provided to ensure an orderly meeting.
Board and executive committee updates
All board members and executive officers were present, including committee chairs for ESG, Talent, Portfolio Development, and Audit.
The independent registered public accounting firm and inspector of election were also in attendance.
Shareholder proposals
Proposals included election of directors, advisory vote on executive compensation, amendment of the 2021 Incentive Stock Plan, and ratification of the accounting firm.
The board unanimously recommended voting in favor of all proposals.
Latest events from Organon
- Revenue and net income fell as biosimilar growth offset declines in core brands; Sun Pharma deal advances.OGN
Q2 202631 Jul 2026 - Merger with Sun Pharma USA and related executive compensation were approved by shareholders.OGN
EGM 202623 Jul 2026 - Stockholders to vote on Sun Pharma merger amid litigation and new proxy disclosures.OGN
Proxy filing17 Jul 2026 - All management proposals passed, with strong financial growth and a focus on women's health and deleveraging.OGN
AGM 20259 Jul 2026 - Shareholders to vote on $14.00 per share all-cash merger with Sun Pharma USA, board recommends approval.OGN
Proxy filing17 Jun 2026 - Shareholders will soon vote on the Sun Pharma acquisition amid strong performance and cultural focus.OGN
Proxy filing11 Jun 2026 - Shareholders to vote on $14.00 per share all-cash merger with Sun Pharma USA, closing expected in 2027.OGN
Proxy filing1 Jun 2026 - Net income rose 68% to $146 million on $1.46 billion revenue, with a pending merger and remediation.OGN
Q1 20264 May 2026 - Organon and Sun Pharma announce a merger with strong employee protections and a pending shareholder vote.OGN
Proxy filing30 Apr 2026